ArticleFrontiers in cellular neuroscience2014
Nanobodies as modulators of inflammation: potential applications for acute brain injury.
Article in Frontiers in cellular neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Beyond amyloid: nanobody-mediated neuroinflammatory therapy for Alzheimer's disease.Translational neurodegeneration · 2025Review
- Nanobody-based Pannexin1 channel inhibitors increase survival after cardiac ischemia/reperfusion.Cell and tissue research · 2025Article
- Adeno-associated viral vectors encoding anti-P2X7 nanobodies reduce graft-versus-host disease in a humanised mouse model.Clinical & translational immunology · 2025Article
- Nanoparticle targeting strategies for traumatic brain injury.Journal of neural engineering · 2024Review
- Selective modulation of activated protein C activities by a nonactive site-targeting nanobody library.Blood advances · 2023Article
- Nanobodies: Robust miniprotein binders in biomedicine.Advanced drug delivery reviews · 2023Review
- Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors.International journal of molecular sciences · 2023Review
- Nanobodies: an unexplored opportunity to combat COVID-19.Journal of biomolecular structure & dynamics · 2022Article
- Preparation of a Nanobody Specific to Dectin 1 and Its Anti-inflammatory Effects on Fungal Keratitis.International journal of nanomedicine · 2022Article
- The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.Molecular biology reports · 2022Review
- Transportation of Single-Domain Antibodies through the Blood-Brain Barrier.Biomolecules · 2021Review
- Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials.ACS applied materials & interfaces · 2021Article
- A guide to: generation and design of nanobodies.The FEBS journal · 2021Review
- Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.International journal of nanomedicine · 2021Review
- The Therapeutic Potential of Nanobodies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
- Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration.Therapeutic advances in medical oncology · 2020Article
- Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells.Molecular pharmaceutics · 2019Article
- The Camel Adaptive Immune Receptors Repertoire as a Singular Example of Structural and Functional Genomics.Frontiers in genetics · 2019Review
- The current perspectives of dromedary camel stem cells research.International journal of veterinary science and medicine · 2018Review
- Identification and characterization of Nanobodies targeting the EphA4 receptor.The Journal of biological chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanobodies are single domain antibodies derived from llama heavy-chain only antibodies (HCAbs). They represent a new generation of biologicals with unique properties: nanobodies show excellent tissue distribution, high temperature and pH stability, are easy to produce recombinantly and can readily be converted into different formats such as Fc-fusion proteins or hetero-dimers. Moreover, nanobodies have the unique ability to bind molecular clefts, such as the active site of enzymes, thereby interfering with the function of the target protein. Over the last decade, numerous nanobodies have been developed against proteins involved in inflammation with the aim to modulate their immune functions. Here, we give an overview about recently developed nanobodies that target immunological pathways linked to neuroinflammation. Furthermore, we highlight strategies to modify nanobodies so that they can overcome the blood brain barrier and serve as highly specific therapeutics for acute inflammatory brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.